Abstract

Small cell lung cancer (SCLC) has a clinical course that is distinct from its more common counterpart non-small cell lung cancer. SCLC continues to be a major clinical problem, with an aggressive clinical course and short disease-free duration after initial therapy. Current optimal treatment consists of chemotherapy with platinum-etoposide, given concurrently with thoracic irradiation in patients with limited stage disease and chemotherapy alone in those with extensive stage. Prophylactic cranial irradiation (PCI) is recommended for patients who have responded to initial therapy, as it not only decreases the risk of brain metastases and but also improves overall survival. Newer targeted agents are currently being evaluated for this disease.

Original languageEnglish (US)
Pages (from-to)1043-1051
Number of pages9
JournalIndian Journal of Medical Research
Volume137
Issue number6
StatePublished - Jun 1 2013

Fingerprint

Small Cell Lung Carcinoma
Chemotherapy
Cells
Irradiation
Cranial Irradiation
Drug Therapy
Etoposide
Platinum
Non-Small Cell Lung Carcinoma
Brain
Thorax
Therapeutics
Neoplasm Metastasis
Survival

Keywords

  • Cisplatin
  • Etoposide
  • Prophylactic cranial irradiation
  • Small cell lung cancer
  • Thoracic radiation

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Current concepts in the management of small cell lung cancer. / Ganti, Apar Kishor P; West, William W.; Zhen, Weining.

In: Indian Journal of Medical Research, Vol. 137, No. 6, 01.06.2013, p. 1043-1051.

Research output: Contribution to journalReview article

@article{a779c4f8eb6346579559f099484f0646,
title = "Current concepts in the management of small cell lung cancer",
abstract = "Small cell lung cancer (SCLC) has a clinical course that is distinct from its more common counterpart non-small cell lung cancer. SCLC continues to be a major clinical problem, with an aggressive clinical course and short disease-free duration after initial therapy. Current optimal treatment consists of chemotherapy with platinum-etoposide, given concurrently with thoracic irradiation in patients with limited stage disease and chemotherapy alone in those with extensive stage. Prophylactic cranial irradiation (PCI) is recommended for patients who have responded to initial therapy, as it not only decreases the risk of brain metastases and but also improves overall survival. Newer targeted agents are currently being evaluated for this disease.",
keywords = "Cisplatin, Etoposide, Prophylactic cranial irradiation, Small cell lung cancer, Thoracic radiation",
author = "Ganti, {Apar Kishor P} and West, {William W.} and Weining Zhen",
year = "2013",
month = "6",
day = "1",
language = "English (US)",
volume = "137",
pages = "1043--1051",
journal = "Indian Journal of Medical Research",
issn = "0971-5916",
publisher = "Indian Council of Medical Research",
number = "6",

}

TY - JOUR

T1 - Current concepts in the management of small cell lung cancer

AU - Ganti, Apar Kishor P

AU - West, William W.

AU - Zhen, Weining

PY - 2013/6/1

Y1 - 2013/6/1

N2 - Small cell lung cancer (SCLC) has a clinical course that is distinct from its more common counterpart non-small cell lung cancer. SCLC continues to be a major clinical problem, with an aggressive clinical course and short disease-free duration after initial therapy. Current optimal treatment consists of chemotherapy with platinum-etoposide, given concurrently with thoracic irradiation in patients with limited stage disease and chemotherapy alone in those with extensive stage. Prophylactic cranial irradiation (PCI) is recommended for patients who have responded to initial therapy, as it not only decreases the risk of brain metastases and but also improves overall survival. Newer targeted agents are currently being evaluated for this disease.

AB - Small cell lung cancer (SCLC) has a clinical course that is distinct from its more common counterpart non-small cell lung cancer. SCLC continues to be a major clinical problem, with an aggressive clinical course and short disease-free duration after initial therapy. Current optimal treatment consists of chemotherapy with platinum-etoposide, given concurrently with thoracic irradiation in patients with limited stage disease and chemotherapy alone in those with extensive stage. Prophylactic cranial irradiation (PCI) is recommended for patients who have responded to initial therapy, as it not only decreases the risk of brain metastases and but also improves overall survival. Newer targeted agents are currently being evaluated for this disease.

KW - Cisplatin

KW - Etoposide

KW - Prophylactic cranial irradiation

KW - Small cell lung cancer

KW - Thoracic radiation

UR - http://www.scopus.com/inward/record.url?scp=84879533661&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879533661&partnerID=8YFLogxK

M3 - Review article

VL - 137

SP - 1043

EP - 1051

JO - Indian Journal of Medical Research

JF - Indian Journal of Medical Research

SN - 0971-5916

IS - 6

ER -